29
2.5. Addressing Health Inequities and Barriers to AF
Management
COR LOE
Recommendation
1 B-NR 1. Patients with AF, regardless of sex and gender diversity,
race and ethnicity, or adverse social determinants of health
(SDOH),* should be equitably offered guideline-directed
stroke risk reduction therapies as well as rate or rhythm
control strategies and LRFM as indicated to improve QOL
and prevent adverse outcomes.
* Including lower income, lower education, inadequate or lack of insurance coverage, or
rurality.
3. Shared Decision-Making in AF Management
COR LOE
Recommendation
2b B-R 1. In patients with AF, the use of evidence-based decision
aids might be useful to guide stroke reduction therapy
treatment decisions throughout the disease course to improve
engagement, decisional quality, and patient satisfaction.
Table 6. CHARGE-AF Risk Score for Detecting Incident AF*
Variable (X)
Estimated β
coefficient (SE) HR (95% CI)
Age (per 5-y increment) 0.508 (0.022)
1.66 (1.59–1.74)
White Race 0.465 (0.093) 1.59 (1.33–1.91)
Height (per 10-cm increment) 0.248 (0.036) 1.28 (1.19–1.38)
Weight (per 15-kg increment) 0.115 (0.033) 1.12 (1.05–1.20)
Systolic BP (per 20-mm Hg increment) 0.197 (0.033) 1.22 (1.14–1.30)
Diastolic BP (per 10-mm Hg increment) -0.101 (0.032) 0.90 (0.85–0.96)
Smoking (current versus former/never) 0.359 (0.063) 1.42 (1.25–1.60)
Diabetes (yes) 0.237 (0.073) 1.27 (1.64–2.48)
Myocardial infarction (yes) 0.496 (0.089) 1.64 (1.38–1.96)
* Five-year risk is given by: 1 – 0.9718412736
exp(ΣβX – 12.4411305)
, where β is the regression
coefficient (column 2) and X is the level of each variable risk factor.
Table 6 does not encompass all complications.
4. Clinical Evaluation
4.1. Risk Stratification and Population Screening
Management
